news
FDA approves Gilotrif™ (afatinib) as first-line treatment for lung cancer patients with EGFR mutations
16 July 2013 | By Boehringer Ingelheim
First approval for afatinib, the frontrunner from Boehringer Ingelheim’s new oncology pipeline...
List view / Grid view
EGFR
article
Gene to drugs: can expression be the key to new discoveries?
25 February 2013 | By Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky
Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new…
